Performance of Diuretic Stress Test in Predicting Short Term Renal Recovery in Oliguric Critically-ill Patients Recovery in the Short Term

Centre Hospitalier Universitaire de Saint Etienne

Status: Terminated

Conditions: Oliguria; Critical Illness

Treatments: Drug: Furosemide

Study type: Interventional

Funder types: Other

Identifiers

NCT02800135

2014-005146-22 (EudraCT Number)

1408024

141521A-11 (Other Identifier)

Details and patient eligibility

About

Acute kidney injury (AKI) is a common disorder and associated with high morbidity and mortality. However, distinguishing transient AKI from persistent AKI may help in individualizing treatment and limit short and long term consequences of AKI. Previous studies suggested usual urinary indices to perform poorly for separating transient from persistent AKI in an unselected population of critically ill patients. The recent KDIGO (Kidney Disease Improving Global Outcomes) guidelines underlined the need for additional strategies in estimating renal short term prognosis.

Recently, a Furosemide stress test (FST) was validated in a cohort of unselected critically ill patients. This stress test performance was found to be good in predicting capacity to identify those patients that will progress to advanced stage AKI. Additionally, FST performance was higher than those of usual renal biomarker. The limited sample size of this preliminary study however precluded adjustment for usual confounders including oliguria.

The primary objective of this study is to assess diagnostic performance of FST in differentiating transient and persistent AKI. Secondary objectives are to assess diagnostic performance of FST in predicting need for renal replacement therapy, and to confirm FST results after adjustment for confounders.

Enrollment: 93 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients (age > 18 y.o)
• AKI stage 1 or more according to KDIGO
• Oliguria as defined by an oliguria lower than 0.5 mL/Kg
• Affiliation to the National Medical Insurance

Exclusion criteria

• Pregnancy
• Chronic kidney disease stage 4 or more
• Need for fluid bolus (>1000 mL crystalloids or equivalent) or need for vasopressors increases or introduction in the 2 hours preceding inclusion
• Evidence of obstructive renal failure

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

93 participants in 1 patient group

Furosemide stress test

Experimental group

Treatment:

Drug: Furosemide